Literature DB >> 16118101

Pathways to the diagnosis of prostate cancer in a British city. A population-based study.

Jacqueline Barrett1, William Hamilton.   

Abstract

OBJECTIVE: To identify the pathways leading to the diagnosis of prostate cancer from a UK population perspective, including the role of prostate-specific antigen (PSA) testing.
MATERIAL AND METHODS: We studied all 217 prostate cancers occurring in the region covered by Exeter Primary Care Trust, Devon, UK (population 128 700) between 1998 and 2002. The general practitioner's records for 2 years before diagnosis were used to identify the category of pathway to diagnosis.
RESULTS: Symptomatic presentation to primary care initiated the diagnostic process in 166/217 men (76%). The presenting symptoms were lower urinary tract symptoms (LUTS) in 151 men (70%), systemic symptoms and no LUTS in 12 (6%) and bowel symptoms with a rectal examination revealing an abnormal prostate in 3 (1%). Eighteen cases (8%) were diagnosed as a result of PSA screening in asymptomatic men. Diagnosis as an inpatient accounted for 33 cases (15%), 25 of whom (11%) had been admitted with urological problems, and 4% of cases had been admitted for non-urological problems. Of the 151 men who presented with LUTS, 91 (60%) had a PSA test in primary care, 15 (10%) had one in secondary care and 39 (17%) had a prostatectomy that revealed a cancer that had not previously been suspected. Most prostate cancers were diagnosed after presentation to primary care with LUTS. Presentation with disseminated disease was rare.
CONCLUSION: Screening by means of PSA testing remains uncommon in this area of the UK, in contrast to the situation in other countries. Most PSA tests performed in patients with prostate cancer were diagnostic rather than screening tests.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16118101     DOI: 10.1080/00365590510031282

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  8 in total

1.  Clinical features of prostate cancer before diagnosis: a population-based, case-control study.

Authors:  William Hamilton; Deborah J Sharp; Tim J Peters; Alison P Round
Journal:  Br J Gen Pract       Date:  2006-10       Impact factor: 5.386

Review 2.  The association between symptoms and bladder or renal tract cancer in primary care: a systematic review.

Authors:  Mia Schmidt-Hansen; Sabine Berendse; William Hamilton
Journal:  Br J Gen Pract       Date:  2015-11       Impact factor: 5.386

3.  Five misconceptions in cancer diagnosis.

Authors:  William Hamilton
Journal:  Br J Gen Pract       Date:  2009-06       Impact factor: 5.386

4.  Routes to diagnosis for cancer - determining the patient journey using multiple routine data sets.

Authors:  L Elliss-Brookes; S McPhail; A Ives; M Greenslade; J Shelton; S Hiom; M Richards
Journal:  Br J Cancer       Date:  2012-09-20       Impact factor: 7.640

5.  Symptoms in primary care with time to diagnosis of brain tumours.

Authors:  Mio Ozawa; Paul M Brennan; Karolis Zienius; Kathreena M Kurian; William Hollingworth; David Weller; Willie Hamilton; Robin Grant; Yoav Ben-Shlomo
Journal:  Fam Pract       Date:  2018-09-18       Impact factor: 2.267

6.  Systematic review and meta-analysis of the diagnostic accuracy of prostate-specific antigen (PSA) for the detection of prostate cancer in symptomatic patients.

Authors:  Samuel W D Merriel; Lucy Pocock; Emma Gilbert; Sam Creavin; Fiona M Walter; Anne Spencer; Willie Hamilton
Journal:  BMC Med       Date:  2022-02-07       Impact factor: 8.775

7.  Pathways to the diagnosis of lung cancer in the UK: a cohort study.

Authors:  Jacqueline Barrett; William Hamilton
Journal:  BMC Fam Pract       Date:  2008-05-18       Impact factor: 2.497

8.  Changing trends in symptomatology, diagnostics, stage and survival of prostate cancer in Northern Finland during a period of 20 years.

Authors:  Outi T Kavasmaa; Dimitri B Tyomkin; Aare Mehik; Teija M Parpala; Panu Tonttila; Ilkka Paananen; Pekka Kunelius; Markku H Vaarala; Pasi Ohtonen; Pekka A Hellström
Journal:  World J Surg Oncol       Date:  2013-10-05       Impact factor: 2.754

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.